In this issue of Blood , Baenziger and colleagues demonstrate that chronic triggering of TLR7 in mice using soluble synthetic or HIV-1–derived TLR7 ligands leads to immune activation and disruption of lymphoid architecture similar to those observed in chronic HIV-1 infection in humans. The link
No takes yet. Share an insight, caveat, or question.
Chang et al. (2009) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: